Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. (Q39959245)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Azucena Esparís-Ogando

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Ruth Rodriguez-Barrueco

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Joana Borges

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

6

A Pandiella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

L Ferreira

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

17 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

1860-1869

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18641009%20AND%20SRC:MED&resulttype=core&format=json

ERBB receptors and cancer: the complexity of targeted inhibitors

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Function of the IGF-I receptor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

The insulin-like growth factor 1 receptor in cancer: old focus, new future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

p21Waf1/Cip1 as a therapeutic target in breast and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

A novel aspartyl proteinase from apocrine epithelia and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406

Towards novel anti-cancer strategies based on cystatin function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN406